- Home
- IQV vs ED Comparison
IQV vs ED Comparison
Compare IQV & ED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IQV | ED |
|---|---|---|
| Founded | 1982 | 1884 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4B | 34.6B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | IQV | ED |
|---|---|---|
| Price | $243.25 | $99.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 13 |
| Target Price | ★ $240.60 | $104.54 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 02-05-2026 | 02-19-2026 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | N/A | ★ 7.94 |
| EPS | ★ 7.30 | 5.74 |
| Revenue | $15,904,000,000.00 | ★ $16,593,000,000.00 |
| Revenue This Year | $6.15 | $11.45 |
| Revenue Next Year | $5.39 | $3.35 |
| P/E Ratio | $33.30 | ★ $17.47 |
| Revenue Growth | 3.85 | ★ 10.39 |
| 52 Week Low | $134.65 | $87.28 |
| 52 Week High | $246.71 | $114.87 |
Technical Indicators
Market Signals| Indicator | IQV | ED |
|---|---|---|
| Relative Strength Index (RSI) | 72.42 | 51.41 |
| Support Level | $239.00 | $96.96 |
| Resistance Level | $246.71 | $101.27 |
| Average True Range (ATR) | 4.59 | 1.41 |
| MACD | 1.89 | 0.07 |
| Stochastic Oscillator | 86.01 | 54.52 |
Price Performance
Historical ComparisonAbout IQV IQVIA Holdings Inc.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
About ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.